ExtraCorporeal Membrane Oxygenation (ECMO)PREVENT-ECMONCT07709546
Closed Incision NPWT to Prevent Wound Complications Post-ECMO
A study testing Prophylactic Closed-Incision Negative Pressure Wound Therapy and Standard Wound Dressing in people with ExtraCorporeal Membrane Oxygenation (ECMO) and Wound Complications, run by St. Antonius Hospital.
Trial summary
Patients undergoing extracorporeal membrane oxygenation (ECMO) are at increased risk of wound complications at the vascular access site after decannulation. These complications may delay recovery and increase healthcare burden. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- ExtraCorporeal Membrane Oxygenation (ECMO), Wound Complications, Surgical Site Infection (SSI)
- What is being tested?
- Prophylactic Closed-Incision Negative Pressure Wound Therapy and Standard Wound Dressing
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 144 participants
- Where
- No sites listed yet
- Study dates
- 13 Jul 2026to 18 Mar 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is aged 18 years or older
- Is currently receiving ECMO therapy and is eligible for weaning from the device
- The patient must have at least one cannula inserted at the groin site
- (Proxy) informed consent
Who cannot join
- Duration ECMO run < 24 hours
- Expected death within 24 hours after decannulation
- Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+)
- Wound closure is not possible after decannulation.
- Presence of drain in the wound site
- Participants who are not proficient in Dutch or English, or whose legal representative is not proficient, if applicable
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Prophylactic Effect of Closed Incision Negative Pressure Therapy on Vascular Entry Site Complications Following ECMO Decannulation
Patients undergoing extracorporeal membrane oxygenation (ECMO) are at increased risk of wound complications at the vascular access site after decannulation. These complications may delay recovery and increase healthcare burden. Closed incision negative pressure wound therapy (NPWT) may improve wound healing by reducing fluid accumulation and supporting the incision. This study evaluates whether prophylactic NPWT reduces wound complications compared to standard wound care following ECMO decannulation.
Read the detailed description
Wound healing at the vascular access site is frequently impaired in patients following extracorporeal membrane oxygenation (ECMO). Cannulation-related wound complications (CRWCs), most commonly occurring in the groin, contribute to patient discomfort, delayed recovery, increased nursing workload, and higher healthcare costs.
The aim of this study is to evaluate whether prophylactic negative pressure wound therapy (NPWT) reduces the incidence of CRWCs following ECMO decannulation compared to standard wound care. The primary objective of this randomized controlled trial is to determine whether NPWT is superior to standard wound care with respect to the occurrence of CRWCs within 30 days after decannulation.
This study is designed as a prospective, multi-center, randomized, open-label trial. Adult patients (≥18 years) who have undergone ECMO treatment will be eligible for inclusion.
Following ECMO decannulation, patients in the intervention group will receive prophylactic NPWT applied to the closed groin wound for seven days. Patients in the control group will receive standard wound care using sterile adhesive dressings according to local protocols.
The primary outcome is the incidence of CRWCs within 30 days after ECMO decannulation. Secondary outcomes include the proportion of patients requiring premature discontinuation of NPWT (<7 days) and reasons for discontinuation, length of stay in the intensive care unit and hospital, wound healing status at discharge, and wound-related complications. In addition, patient-reported outcomes will be assessed, including wound-related quality of life (Wound-QoL-14) and general health-related quality of life (EQ-5D-5L) at three months after discharge. Healthcare utilization, including medical consumption and productivity losses, will also be evaluated using validated questionnaires, and total healthcare costs will be assessed up to three months post-discharge.
Patients receiving ECMO are at high risk of complications, including CRWCs, and optimal wound management is essential.
Prophylactic NPWT is already widely used in various surgical settings to support wound healing in high-risk patients. Studies in vascular and other surgical populations have shown that NPWT on groin incisions can significantly reduce surgical site infections and wound-related complications compared to standard dressings. The mechanism of NPWT, including removal of exudate and infectious material, reduction of edema and seroma formation, and stabilization of wound edges, directly targets key factors involved in impaired wound healing after ECMO decannulation.
Participation in this study is associated with minimal additional burden. The intervention is applied as part of routine postoperative care and does not extend beyond the hospital stay. Wound assessments follow standard clinical protocols. Additional data on quality of life and healthcare use will be collected through a digital questionnaire three months after discharge.
Participation is not expected to introduce significant additional risks, while it may offer potential benefits through improved wound healing and reduced complications.
- Conditions
- ExtraCorporeal Membrane Oxygenation (ECMO), Wound Complications, Surgical Site Infection (SSI)
- Being tested
- Prophylactic Closed-Incision Negative Pressure Wound Therapy, Standard Wound Dressing
- Keywords
- ECMO, Extracorporeal Membrane Oxygenation, Negative Pressure Wound Therapy, NPWT, Prevena, Closed Incision Negative Pressure Therapy, ciNPT, Wound Complications, Surgical Site Infection, CRWC, Groin wound, Vascular access site
- Medical subject headings
- Surgical Wound Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prophylactic Closed-Incision Negative Pressure Wound TherapyDevice
Also called NPWT, Closed-Incision NPWT, ciNPWT, Prevena™ system
Prophylactic closed-incision negative pressure wound therapy (NPWT) is applied immediately following ECMO decannulation to closed groin wounds. The system consists of a sealed dressing connected to a continuous vacuum device set at -125 mmHg and is maintained for seven days without routine dressing changes. This intervention is specifically used to prevent wound complications in high-risk ECMO patients and is applied to one or both groins depending on cannulation.
Standard Wound DressingDevice
Also called Standard Wound Care, Sterile Wound Dressing, Conventional Wound Dressing
Standard wound dressing is applied to closed groin wounds immediately following ECMO decannulation under sterile conditions. The dressing consists of a conventional sterile adhesive covering without the application of negative pressure or active fluid management. Dressings are changed as clinically indicated according to local standard care protocols.
| Study group | Role | What they receive |
|---|---|---|
| Prophylactic NPWT | Experimental | Following ECMO decannulation, a prophylactic negative pressure wound therapy (NPWT) system is applied under sterile conditions to the closed groin wound in the operating room or ICU. The NPWT system consists of a closed-incision dressing connected to a continuous vacuum device set at -125 mmHg and is maintained for seven days without routine dressing changes. Wound exudate is collected in a canister and monitored during treatment. Receives: Device: Prophylactic Closed-Incision Negative Pressure Wound Therapy |
| Standard Wound Care | Active comparator | Following ECMO decannulation, a sterile adhesive dressing is applied under sterile conditions to the closed groin wound in the operating room or ICU. Dressings are managed and changed according to local standard care protocols. Receives: Device: Standard Wound Dressing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cannula-related wound complications (CRWCs)
Cannula-related wound complications (CRWCs) are defined as the occurrence of at least one of the following conditions at the groin cannulation site: hematoma, seroma or fluid collection (with or without exudate leakage), excessive wound exudate, wound dehiscence, fibrinous slough or necrosis, or surgical site infection (SSI) classified according to CDC criteria. In patients with bilateral groin cannulation, the presence of a CRWC at either site is considered as a positive outcome.
Measured: 30 days after ECMO decannulation
Secondary outcomes (10)
Early removal of NPWT
Proportion of patients in whom the NPWT system is removed before completion of the intended 7-day treatment period.
Measured: Within 7 days after ECMO decannulation
Reasons for early NPWT removal
Documented reasons for premature discontinuation of NPWT prior to 7 days, including medical, technical, or patient-related factors.
Measured: Within 7 days after ECMO decannulation
Length of hospital stay
Hospital length of stay in days, calculated from initial hospital admission to final hospital discharge, including interhospital transfers as part of a single continuous hospital stay.
Measured: From initial hospital admission until final hospital discharge (variable duration depending on individual hospital stay).
Length of ICU stay
Duration of ICU stay in days, calculated from ICU admission to ICU discharge.
Measured: From ICU admission until ICU discharge, with duration calculated as the number of days between ICU admission and ICU discharge. (variable duration depending on individual ICU stay)
Medical interventions related to wound complications
Occurrence of medical interventions related to cannula-related wound complications, including duration of intensive wound care, use of advanced wound dressings, negative pressure wound therapy (VAC), antibiotic treatment, debridement, surgical interventions (including muscle flap repair), and other wound-related treatments.
Measured: Within 30 days after ECMO decannulation
Nursing workload and wound care material use
Daily nursing time spent on wound care and type and quantity of wound care materials used, recorded until hospital discharge.
Measured: From decannulation until hospital discharge
Number of participants with a healed groin cannulation site
A groin cannulation site is considered healed when complete skin closure has been achieved, no wound dressings or dressing changes are required, and no further wound-related interventions are indicated, based on clinical assessment.
Measured: Assessed at final hospital discharge, occurring at a variable time point depending on the duration of the individual hospital stay.
EQ-5D-5L index score
Health-related quality of life measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Responses are converted into an EQ-5D-5L index value using the applicable value set for economic evaluation and quality-adjusted life year (QALY) calculations. Higher index scores indicate better health-related quality of life. The index score ranges from values below 0 (health states considered worse than death) to 1.0 (full health).
Measured: At hospital discharge and 3 months after final hospital discharge.
Wound-QoL-14 total score in patients discharged with a wound-related complication
Wound-related quality of life measured using the Wound Quality of Life-14 (Wound-QoL-14) questionnaire in patients discharged from the hospital with a clinically relevant wound complication (CRWC). The Wound-QoL-14 assesses the impact of wound-related symptoms, limitations in daily activities, and psychological burden. Scores are calculated according to the questionnaire scoring manual, with higher scores indicating worse wound-related quality of life.
Measured: 3 months after final hospital discharge.
Healthcare utilization and costs
Healthcare utilization and associated costs assessed using the iMTA Medical Consumption Questionnaire (iMCQ), including home care involvement, and productivity losses measured using the iMTA Productivity Cost Questionnaire (iPCQ).
Measured: Up to 3 months after hospital discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start13 Jul 2026 (estimated)
- Primary completion18 Nov 2028 (estimated)
- Study completion18 Mar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ExtraCorporeal Membrane Oxygenation (ECMO)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a prospective, multi-center, randomized controlled open-label trial with a parallel assignment design. Participants are randomized in a 1:1 ratio to receive either prophylactic negative pressure wound therapy (NPWT) or standard wound care, using block randomization stratified by center, ECMO modality (veno-venous \[VV\] ECMO or veno-arterial \[VA\] ECMO, including relevant triple cannulation modes or ECPR), and the number of cannulated groins (one versus two). Following ECMO decannulation, the allocated treatment is applied immediately and maintained for seven days. In patients with bilateral groin cannulation, treatment is applied bilaterally. The study is open-label for patients and clinical staff, while outcome assessment is performed by blinded specialized wound nurses based on standardized photographs and objective parameters at days 8, 15, and 30.
- Masking
- None (open label)
- Enrolment
- 144 participants (estimated)
Sponsor and investigators
- Lead sponsor
- St. Antonius Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- St. Antonius Onderzoeksfonds, St. Antonius innovatiefonds
- Responsible party
- Principal investigator, dr. Peter Noordzij, MD PhD, St. Antonius Hospital
- Investigators
- Erik Scholten, MD, Principal investigator, St. Antonius Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07709546
- Sponsor's protocol ID
- NL-011305 • PI-01.01
- Acronym
- PREVENT-ECMO
- Status last verified
- Jul 2026
- First submitted
- 23 Jun 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Individual participant data will be shared upon reasonable request, after approval by the study steering committee and in accordance with agreements between participating centers and applicable data protection regulations.
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prophylactic Effect of Closed Incision Negative Pressure Therapy on Vascular Entry Site Complications Following ECMO Decannulation
- ClinicalTrials.gov ID
- NCT07709546
- Acronym / sponsor ID
- PREVENT-ECMO / NL-011305 • PI-01.01
- Conditions
- ExtraCorporeal Membrane Oxygenation (ECMO), Wound Complications, Surgical Site Infection (SSI)
- Keywords
- ECMO, Extracorporeal Membrane Oxygenation, Negative Pressure Wound Therapy, NPWT, Prevena, Closed Incision Negative Pressure Therapy, ciNPT, Wound Complications
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 144 participants (estimated)
- Lead sponsor
- St. Antonius HospitalUniversity, hospital or other
- Collaborators
- St. Antonius Onderzoeksfonds, St. Antonius innovatiefonds
- Study start
- 13 Jul 2026 (estimated)
- Primary completion
- 18 Nov 2028 (estimated)
- Study completion
- 18 Mar 2029 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients undergoing extracorporeal membrane oxygenation (ECMO) are at increased risk of wound complications at the vascular access site after decannulation. These complications may delay recovery and increase healthcare burden. Closed incision negative pressure wound therapy (NPWT) may improve wound healing by reducing fluid accumulation and supporting the incision. This study evaluates whether prophylactic NPWT reduces wound complications compared to standard wound care following ECMO decannulation.
Detailed description
Wound healing at the vascular access site is frequently impaired in patients following extracorporeal membrane oxygenation (ECMO). Cannulation-related wound complications (CRWCs), most commonly occurring in the groin, contribute to patient discomfort, delayed recovery, increased nursing workload, and higher healthcare costs.
The aim of this study is to evaluate whether prophylactic negative pressure wound therapy (NPWT) reduces the incidence of CRWCs following ECMO decannulation compared to standard wound care. The primary objective of this randomized controlled trial is to determine whether NPWT is superior to standard wound care with respect to the occurrence of CRWCs within 30 days after decannulation.
This study is designed as a prospective, multi-center, randomized, open-label trial. Adult patients (≥18 years) who have undergone ECMO treatment will be eligible for inclusion.
Following ECMO decannulation, patients in the intervention group will receive prophylactic NPWT applied to the closed groin wound for seven days. Patients in the control group will receive standard wound care using sterile adhesive dressings according to local protocols.
The primary outcome is the incidence of CRWCs within 30 days after ECMO decannulation. Secondary outcomes include the proportion of patients requiring premature discontinuation of NPWT (<7 days) and reasons for discontinuation, length of stay in the intensive care unit and hospital, wound healing status at discharge, and wound-related complications. In addition, patient-reported outcomes will be assessed, including wound-related quality of life (Wound-QoL-14) and general health-related quality of life (EQ-5D-5L) at three months after discharge. Healthcare utilization, including medical consumption and productivity losses, will also be evaluated using validated questionnaires, and total healthcare costs will be assessed up to three months post-discharge.
Patients receiving ECMO are at high risk of complications, including CRWCs, and optimal wound management is essential.
Prophylactic NPWT is already widely used in various surgical settings to support wound healing in high-risk patients. Studies in vascular and other surgical populations have shown that NPWT on groin incisions can significantly reduce surgical site infections and wound-related complications compared to standard dressings. The mechanism of NPWT, including removal of exudate and infectious material, reduction of edema and seroma formation, and stabilization of wound edges, directly targets key factors involved in impaired wound healing after ECMO decannulation.
Participation in this study is associated with minimal additional burden. The intervention is applied as part of routine postoperative care and does not extend beyond the hospital stay. Wound assessments follow standard clinical protocols. Additional data on quality of life and healthcare use will be collected through a digital questionnaire three months after discharge.
Participation is not expected to introduce significant additional risks, while it may offer potential benefits through improved wound healing and reduced complications.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study is a prospective, multi-center, randomized controlled open-label trial with a parallel assignment design. Participants are randomized in a 1:1 ratio to receive either prophylactic negative pressure wound therapy (NPWT) or standard wound care, using block randomization stratified by center, ECMO modality (veno-venous [VV] ECMO or veno-arterial [VA] ECMO, including relevant triple cannulation modes or ECPR), and the number of cannulated groins (one versus two). Following ECMO decannulation, the allocated treatment is applied immediately and maintained for seven days. In patients with bilateral groin cannulation, treatment is applied bilaterally. The study is open-label for patients and clinical staff, while outcome assessment is performed by blinded specialized wound nurses based on standardized photographs and objective parameters at days 8, 15, and 30.
| Arm | Type | Receives |
|---|---|---|
| Prophylactic NPWT | Experimental | Device: Prophylactic Closed-Incision Negative Pressure Wound TherapyFollowing ECMO decannulation, a prophylactic negative pressure wound therapy (NPWT) system is applied under sterile conditions to the closed groin wound in the operating room or ICU. The NPWT system consists of a closed-incision dressing connected to a continuous vacuum device set at -125 mmHg and is maintained for seven days without routine dressing changes. Wound exudate is collected in a canister and monitored during treatment. |
| Standard Wound Care | Active comparator | Device: Standard Wound DressingFollowing ECMO decannulation, a sterile adhesive dressing is applied under sterile conditions to the closed groin wound in the operating room or ICU. Dressings are managed and changed according to local standard care protocols. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patient is aged 18 years or older
- Is currently receiving ECMO therapy and is eligible for weaning from the device
- The patient must have at least one cannula inserted at the groin site
- (Proxy) informed consent
Key exclusion criteria (6 listed)
- Duration ECMO run < 24 hours
- Expected death within 24 hours after decannulation
- Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+)
- Wound closure is not possible after decannulation.
- Presence of drain in the wound site
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prophylactic Closed-Incision Negative Pressure Wound TherapyAlso: NPWT, Closed-Incision NPWT, ciNPWT, Prevena™ systemProphylactic closed-incision negative pressure wound therapy (NPWT) is applied immediately following ECMO decannulation to closed groin wounds. The system consists of a sealed dressing connected to a continuous vacuum device set at -125 mmHg and is maintained for seven days without routine dressing changes. This intervention is specifically used to prevent wound complications in high-risk ECMO patients and is applied to one or both groins depending on cannulation. | Device | Prophylactic NPWT |
| Standard Wound DressingAlso: Standard Wound Care, Sterile Wound Dressing, Conventional Wound DressingStandard wound dressing is applied to closed groin wounds immediately following ECMO decannulation under sterile conditions. The dressing consists of a conventional sterile adhesive covering without the application of negative pressure or active fluid management. Dressings are changed as clinically indicated according to local standard care protocols. | Device | Standard Wound Care |
Primary outcome
Cannula-related wound complications (CRWCs)
Time frame: 30 days after ECMO decannulation
Cannula-related wound complications (CRWCs) are defined as the occurrence of at least one of the following conditions at the groin cannulation site: hematoma, seroma or fluid collection (with or without exudate leakage), excessive wound exudate, wound dehiscence, fibrinous slough or necrosis, or surgical site infection (SSI) classified according to CDC criteria. In patients with bilateral groin cannulation, the presence of a CRWC at either site is considered as a positive outcome.
10 secondary outcomes
Early removal of NPWT
Time frame: Within 7 days after ECMO decannulation
Reasons for early NPWT removal
Time frame: Within 7 days after ECMO decannulation
Length of hospital stay
Time frame: From initial hospital admission until final hospital discharge (variable duration depending on individual hospital stay).
Length of ICU stay
Time frame: From ICU admission until ICU discharge, with duration calculated as the number of days between ICU admission and ICU discharge. (variable duration depending on individual ICU stay)
Medical interventions related to wound complications
Time frame: Within 30 days after ECMO decannulation
Nursing workload and wound care material use
Time frame: From decannulation until hospital discharge
Number of participants with a healed groin cannulation site
Time frame: Assessed at final hospital discharge, occurring at a variable time point depending on the duration of the individual hospital stay.
EQ-5D-5L index score
Time frame: At hospital discharge and 3 months after final hospital discharge.
Wound-QoL-14 total score in patients discharged with a wound-related complication
Time frame: 3 months after final hospital discharge.
Healthcare utilization and costs
Time frame: Up to 3 months after hospital discharge
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: Yes. Individual participant data will be shared upon reasonable request, after approval by the study steering committee and in accordance with agreements between participating centers and applicable data protection regulations.
Related trials for ExtraCorporeal Membrane Oxygenation (ECMO)
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruitingObservational study
Diagnosis of ECMO Cannula Infection: Prospective Comparison of Sampling Methods
ECMO Cannula Infection, Extracorporeal Membrane Oxygenation Complication
RecruitingObservational study
Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Not yet recruitingPhase 1/2
PACE: Prostacyclin AntiCoagulation in ECMO
ECMO
RecruitingObservational study
Pharmacokinetics of Sedatives and Analgesics During Extracorporeal Membrane Oxygenation (ECMO) Support
Drug Effect
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Erik Scholten, MD principal investigator
St. Antonius Hospital
Questions about this trial
What is this clinical trial studying?
A study testing Prophylactic Closed-Incision Negative Pressure Wound Therapy and Standard Wound Dressing in people with ExtraCorporeal Membrane Oxygenation (ECMO) and Wound Complications, run by St. Antonius Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ineke van de Pol, RN, MSc (+31883206614, i.van.de.pol@antoniusziekenhuis.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cannula-related wound complications (CRWCs) (time frame: 30 days after ECMO decannulation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.